Advertisement


Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab

2024 ASCO Annual Meeting

Advertisement

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Saci-IO HR+ was a randomized phase II investigator-initiated study to evaluate the efficacy of the trop2 directed antibody drug conjugate sacituzumab govitecan with or without the PD-1 inhibitor pembrolizumab in patients with metastatic hormone receptor-positive HER2 negative breast cancer. SG, sacituzumab govitecan, has demonstrated to improve median progression free and overall survival in patients with previously treated hormone receptor positive HER2 negative breast cancer who have received two to four prior chemotherapies for advanced disease as shown in the TROPiCS-02 study. We know that the payload of sacituzumab govitecan SN38 can enhance cytotoxic T-cell effector functions and deplete regulatory T-cells. It can also stimulate the cGAS-STING pathway increasing T-cell infiltration into the tumor, and thus we hypothesized that the combination of SG plus pembrolizumab would enhance the efficacy of SG alone in metastatic hormone receptor positive HER2 negative breast cancer. Saci-IO HR+ randomized patients one-to-one to receive SG plus pembrolizumab or SG alone in the metastatic hormone receptor positive HER2 negative setting. Patients had to have received prior endocrine therapy for advanced disease or progressed on or within 12 months of adjuvant endocrine therapy and they could have received 0 to 1 prior lines of chemotherapy in the advanced setting. The primary endpoint of the study was progression-free survival in the intent-to-treat population and key secondary endpoints were progression-free survival among patients with PD-L1 positive tumors defined using the 22C3 assay and a combined positive score greater than or equal than 1, and also overall survival in both the intent-to-treat and PD-L1 positive populations. The study demonstrated that the addition of pembrolizumab to sacituzumab govitecan did not significantly improve median progression-free survival in the intent-to-treat population. Median PFS with SG plus pembrolizumab was 8.1 months and median PFS with SG alone was 6.2 month, a hazard ratio of 0.81 and P-value of 0.37. In the intent-to-treat population at a median follow-up of 12.5 months, overall survival did not significantly differ between treatment arms. Median OS with SG plus pembrolizumab was 18.5 months versus 18 months with SG alone. And among patients with PD-L1 positive tumors which comprised about 39% of the patient population defined using the CPS cutoff greater than or equal than 1, there was a 4.4 month absolute difference in median progression-free survival between treatment arms favoring the combination that was not statistically significant. Median PFS with SG plus pembrolizumab was 11.1 months and 6.7 months with SG alone, a hazard ratio of 0.62, P-value of 0.23. Again at a median follow-up of 12.5 months, so overall survival data are not mature, among the patients with PD-L1 positive tumors there was a 6-month numerical increase in median OS with the addition of pembrolizumab to SG. Median OS with the combination was 18.5 months compared to 12.5 months with SG alone. Overall, the safety profile of SG plus pembrolizumab was similar to that reported with either agent and there were no new safety signals that were reported. In conclusion, Saci-IO HR+ is the first randomized trial to evaluate the efficacy of a topoisomerase 1 inhibitor ADC in combination with an immune checkpoint inhibitor in breast cancer. This study did not show a statistically significant difference in median progression free and overall survival among patients with metastatic hormone receptor positive HER2 negative breast cancer who had received up to one prior line of chemotherapy in the advanced setting. Overall survival data are not mature and additional follow-up is needed. Among the patients with PD-L1 positive tumors there was a non-significant 4.4 month numerical increase in median PFS and 6-month increase in median OS with the addition of pembrolizumab to SG, and so we do think that the results from this study support further investigation of the combination of SG plus pembrolizumab in patients with PD-L1 positive metastatic hormone receptor positive, HER2 negative breast cancer.

Related Videos

Multiple Myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).

Prostate Cancer

Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).

Lung Cancer

Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases

Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases. Tumor treating fields therapy prolongs time to intracranial disease progression and may postpone whole-brain radiation therapy without declines in quality of life and cognition (Abstract 2008).

Advertisement

Advertisement




Advertisement